Objective
In clinical trials, omega-3 fatty acid supplementation improves
symptoms in psychiatric disorders involving dysregulated mood and impulse
control, yet it is unclear whether in healthy adults omega-3 fatty acid
supplementation affects mood, impulse control and the brain systems
supporting these processes. Accordingly, this study tested the hypotheses
that eciosapentaenoic (EPA) and docosahexaenoic (DHA) acid supplementation
reduces negative affect and impulsive behaviors in healthy adults and that
these changes correspond to alterations in corticolimbic and corticostriatal
brain systems which support affective and impulsive processes.
Methods
Healthy volunteers (N = 272) consuming 300 mg/day or less of EPA and
DHA were enrolled in a double-blind, randomized, placebo controlled clinical
trial. Participants received either capsules providing 1000 mg of EPA and
400 mg of DHA versus identical appearing soybean oil capsules per day for 18
weeks. Negative affect and impulsivity were measured by questionnaire and
ecological momentary assessment (EMA), as well as functional alterations in
corticolimbic and corticostriatal brain systems evoked by standardized fMRI
tasks.
Results
There were no group-by-time interactions for any questionnaire or EMA
measures of mood and impulsivity. Likewise, no group-by-time interactions
were observed for fMRI responses evoked within corticolimbic and
corticostriatal systems.
Conclusions
In healthy adults with low intake of omega-3 fatty acids,
moderate-dose supplementation for 18 weeks did not alter affect or impulsive
behaviors, nor alter corticolimbic and corticostriatal brain
functionality.
Trial Registration
Trial number NCT00663871, URL: https://www.clinicaltrials.gov/ct2/show/NCT00663871?term=NCT00663871&rank=1